June 2022: OCTS Boston

Join KBI Biopharma at ONCO Cell Therapy Summit USA

When: 29-30 JUNE, 2022
Where: Boston, MA

Join KBI Biopharma, Inc. at the OCTS ONCO Cell Therapy Summit this June. Be sure to stop by Stands 7& 8 to chat with KBI Senior Director of Business Development Brian Newsom. We look forward to seeing you there! 

In addition to stopping by KBI's booth, you can also connect with us at the following conference events: 

Process and analytical development for cell therapies
Round Table with panelist Brian Newsom

This panel discussion will address common questions around process and analytical development for cell therapy projects, including:

• When is the appropriate time to make process changes including decisions on harvest dates, ancillary materials, and automation?
• Can conducting too many analytics on my process/product ever be detrimental to a regulatory application?
• Do I have a risk assessment strategy in place for critical material, single-point of failure, supply of critical reagents?
• Can small-scale experiments really help my development work?

How to effectively work with a CDMO to advance your cell therapy program
Tech Talk presented by Brian Newsom

This presentation will cover the necessities in working with a Contract Development and Manufacturing Organization (CDMO) to advance your cell therapy program, including:

• Understanding roles and responsibilities on both sides
• Aligning priorities and incentives
• Mapping out an effective and realistic timeline and budget
• Creating a mitigation strategy with my CDMO in case data on the process and/or the analytics turn out different than expected

About the Conference: 

The Onco Cell Therapy Summit (OCTS) is the only industry-led meeting covering the full range of autologous and allogeneic cell product advancements. A four-tracked agenda, featuring pioneering biopharma, academia, and solution-providers, will address all innovative MoA, manufacturing challenges, and clinical progress of CAR T, TCR T, TILs, Macrophages, and NK cells in treating haematological and solid tumors. Expect to hear from CXOs, VPs, R&D and Process Developers on the opportunities generated from recent clinical and technological data, and how they are tackling the most pressing industry challenges to get effective treatments to patients.

Visit the conference website >>

Let's connect: